As The Going Gets Tough In U.S., Indian Generic Makers Turn To The Land Of The Rising Sun
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Structural shifts in the Japanese pharmaceutical landscape, low generic penetration, a number of patent expiries in the next three years and an increasingly unattractive U.S. market is pushing top Indian drug makers to look at the second-largest market to maintain their growth trajectory
You may also be interested in...
A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.